Abstract
An anti-cancer device having an anti-cancer drug and a blood coagulation factor fixed to a structure. This anti-cancer device is used in transcatheter arterial embolization and needle therapy with advantage and slowly releases the anti-cancer drug over an extended period by staying in the cancer tissue and its nearby area.
Filing date: Feb 14, 1983
Issue date: Aug 20, 1985
Inventors: Izumi Sakamoto, Kunihiko Takagi
Assignee: Unitika Ltd.
download
What is claimed is:
1. A method of transcatheter arterial embolization and needle therapy comprising injecting a patient with composition useful for transcatheter arterial embolization and needle therapy comprising:
- (a) a polymer, wherein said polymer has fixed thereto;
- (b) an anti-cancer drug; and
- (c) a blood coagulation factor, wherein said anti-cancer drug and said blood coagulation factor are fixed to said polymer so as to be capable of sustained release from the polymer at the site of injection.
2. The method as claimed in claim 1, wherein said polymer is a synthetic polymer.
3. The method as claimed in claim 2, wherein said synthetic polymer is silicone.
4. The method as claimed in claim 1, wherein said polymer is selected from the group consisting of cellulosic material, cellulosic material derivative and regenerated cellulose.
5. The method as claimed in claim 4, wherein said cellulosic material derivative is ethyl cellulose.
6. The method as claimed in claim 1, wherein said polymer is bioabsorbable material.
7. The method as claimed in claim 6, wherein said bioabsorbable material is polysaccharide.
8. The method as claimed in claim 7, wherein said polysaccharide is amylose.
9. The method as claimed in claim 7, wherein said polysaccharide is oxidized cellulose.
10. The method as claimed in claim 7, wherein said polysaccharide is chitin.
11. The method as claimed in claim 6, wherein said bioabsorbable material is collagen.
12. The method as claimed in claim 6, wherein said bioabsorbable material is gelatin.
13. The method as claimed in claim 6, wherein said bioabsorbable material is polyamino acid.
14. The method as claimed in claim 13, wherein said polyamino acid is polyglycolic acid.
15. The method as claimed in claim 13, wherein said polyamino acid is polylactic acid.
16. The method as claimed in claim 1, wherein the polymer is in the form of a fibrous assembly.
17. The method as claimed in claim 16, wherein said fibrous assembly is an assembly of oxidized cellulose fiber.
18. The method as claimed in claim 16, wherein said fibrous assembly is an assembly of gelatin fiber.
19. The method as claimed in claim 16, wherein said fibrous assembly is an assembly of chitin fiber.
20. The method as claimed in claim 1, wherein said polymer is in the form of a sponge.
21. The method as claimed in claim 20, wherein said sponge is oxidized cellulose sponge.
22. The method as claimed in claim 20, wherein said sponge is gelatin sponge.
23. The method as claimed in claim 20, wherein said sponge is chitin sponge.
24. The method as claimed in claim 1, wherein said polymer is in the form of a powder.
25. The method as claimed in claim 24, wherein said powder is oxidized cellulose powder.
26. The method as claimed in claim 24, wherein said powder is gelatin powder.
27. The method as claimed in claim 24, wherein said powder is chitin powder.
28. The method as claimed in claim 1, wherein said polymer is in the form of a monofilament.
29. The method as claimed in claim 1, wherein said polymer is in the form of a film.
30. The method as claimed in claim 1, wherein said polymer is in the form of a microcapsule.
31. The method as claimed in claim 1, wherein said anti-cancer drug is an alkylating agent.
32. The method as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and mitomycin.
33. The method as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and bleomycin.
34. The method as claimed in claim 1, wherein said anti-cancer drug is bleomycin.
35. The method as claimed in claim 1, wherein said anti-cancer drug is mitomycin C.
36. The method as claimed in claim 1, wherein said anti-cancer drug is adriamycin.
37. The method as claimed in claim 1, wherein said anti-cancer drug is 5-fluorouracil.
38. The method as claimed in claim 1, wherein said blood coagulation factor is Factor XIII.
39. The method as claimed in claim 1, wherein said blood coagulation factor is thrombin.
40. The method as claimed in claim 1, wherein said blood coagulation factor is a combination of Factor XIII and thrombin.
41. The method as claimed in claim 1, wherein said anti-cancer drug and blood coagulation factor are fixed to the polymer by covalently bonding to the polymer.
42. The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to the said polymer by ionically bonding to said polymer.
43. The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer by adsorption.
44. The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer for entrapping.
45. The method as claimed in claim 1, wherein calcium ion is additionally fixed to said polymer.
46. The method as claimed in claim 1, wherein a pharmaceutical is additionally fixed to said polymer.
47. The method as claimed in claim 46, wherein said pharmaceutical is selected from the group consisting of protease inhibitors, plasma proteins, fibronectin, antiboitics, antivirals, sulfaniamides and anti-infectives.
48. The method as claimed in claim 1, wherein said polymer is a bioabsorbable polymer and wherein said polymer is in the form of a fibrous assembly.
49. The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a sponge.
50. The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a powder.
51. The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a monofilament.
52. The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a film.
53. The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a microcapsule.
54. The method as claimed in claim 1, wherein said polymer is gelatin powder, said anti-cancer drug, and said blood coagulation factor are fixed to said polymer by ionic bonding, entrapping and adsorption, said anti-cancer drug is mitomycin C and wherein said blood coagulation factor is a combination of Factor XIII and thrombin.